GoodRx (GDRX) Insider Kelly Kennedy Buys 73,434 Shares
Kelly Kennedy purchased a substantial number of shares in GoodRx Holdings, reflecting insider confidence.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kelly Kennedy bought 73,434 shares of GoodRx Holdings, Inc. ($GDRX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GDRX is down 2.2% after 1 week, up 14.3% after 1 month and up 23.1% to date (from the $2.73 close on Jun 16, 2026).
GDRX
GoodRx Holdings, Inc.
Key Points
- On June 16, 2026, Kelly Kennedy bought 73,434 shares of GoodRx Holdings, Inc. at $2.61 each, totaling around $192,000.
- The stock price has fluctuated between $1.77 and $5.81 over the past year, currently trading below its 50-day moving average of $3.37.
- Analysts maintain a range of ratings on GoodRx, with Citigroup and TD Cowen both giving it a 'Buy' rating and a target price of $5.00.
Get $GDRX trade alerts by text
We text you when insiders, Congress or big funds trade $GDRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated GoodRx Holdings, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at GoodRx Holdings, Inc.
On June 16, 2026, Kelly Kennedy bought 73,434 shares of GoodRx Holdings, Inc. (GDRX) at a price of $2.61 per share. This purchase is valued at approximately $192,000. It reflects a significant commitment to the company, especially given the current trading environment.
Other Insiders Join the Buying Trend
Kennedy's purchase comes as part of a larger trend among GoodRx insiders. On the same day, Trevor Bezdek, Agnes Rey-Giraud, Scott Wagner, Ronald Bruehlman, and Hirsch Douglas Joseph each bought 73,434 shares. This collective move indicates strong insider confidence in the company's future prospects.
How GoodRx Holdings, Inc. Stock Has Traded
GoodRx shares are currently trading at $2.61, which is below their 50-day moving average of $3.37. The stock has experienced considerable volatility, with a 52-week low of $1.77 and a high of $5.81. This recent insider activity may suggest a belief that the shares are undervalued at this level.
Analysts Set New Price Targets
Analysts have mixed views on GoodRx, with several firms maintaining their ratings recently. On August 21, 2026, Barclays maintained an 'Underweight' rating with a target of $4.00. Meanwhile, Citigroup and TD Cowen both maintained 'Buy' ratings with targets of $5.00. This mix of opinions reflects varied expectations for the company's performance going forward.
What GoodRx Holdings, Inc. Does
GoodRx Holdings, Inc. offers tools that help consumers compare prices and save on prescription drugs in the U.S. Its platform provides access to negotiated prices and healthcare solutions, making it a key player in the healthcare information services sector.
What’s Next for GoodRx
Looking ahead, GoodRx will report its next earnings on November 3, 2026. As the company continues to navigate the healthcare market, this insider buying could be a signal of confidence in its upcoming performance. Remember, the recent 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Kelly Kennedy's Form 4 filing on $GDRX (Jun 16, 2026). Find the original filing: GDRX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts